SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Reports Unaudited First Quarter 2009 Financial Results - Conference call scheduled Friday, May 15, 2009 at 9:00 a.m. ET- - Reaffirmation of 2009 sales projection to be $55 million to $60 million- BEIJING, May 15 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading developer and provider of vaccines in China has announced its unaudited financial results for] [FORM 6-K __________ __________ SINOVAC BIOTECH LTD. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F X Yes _______ No N/A 82- SINOVAC BIOTECH LTD. Form 6-K TABLE OF CONTENTS Page 3 4]